NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Up 42.7% in February

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 230,100 shares, a growth of 42.7% from the January 31st total of 161,300 shares. Based on an average trading volume of 273,600 shares, the short-interest ratio is presently 0.8 days. Currently, 1.6% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 16th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd increased its holdings in NeuroSense Therapeutics by 40.9% during the 3rd quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock valued at $58,000 after purchasing an additional 13,346 shares in the last quarter. Jane Street Group LLC acquired a new position in NeuroSense Therapeutics in the fourth quarter worth $78,000. Finally, Citadel Advisors LLC grew its holdings in shares of NeuroSense Therapeutics by 640.9% during the fourth quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock worth $305,000 after purchasing an additional 219,717 shares during the last quarter. 1.04% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Trading Up 4.8 %

NRSN stock opened at $1.10 on Wednesday. NeuroSense Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.25. The business’s 50 day moving average is $1.13 and its 200-day moving average is $1.12. The firm has a market cap of $15.03 million, a P/E ratio of -1.72 and a beta of 1.27.

NeuroSense Therapeutics (NASDAQ:NRSN) last announced its quarterly earnings results on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.